M. Ya. Kuzmenko
Research Subjects
M. Ya. Kuzmenko has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
A. A. Izmaylov
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
1 shared publication- Alexander V. Petrovsky
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Anastasiia A. Parokonnaia
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Evgeny M. Makarov
Department of Cellular Biochemistry, Max Planck Institute of Biophysical Chemistry, D-37077 Göttingen, Germany
1 shared publication - K. U. Memetov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Larisa V. Khalikova
Tyumen State Medical University of the Ministry of Health of Russia
1 shared publication
Latest Publications
- Open Access
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 69-75
Long-term outcomes in young patients with breast cancer. Multicenter, matched-cohort study
Background. Despite existing clinical guidelines, representative data on breast cancer outcomes in patients aged 25 years and younger remain limited. Aim. To analyze long-term survival in this age group. Materials and methods. We conducted a retrospective, multicenter study that included patients treated between 2008 and 2020. From 552 tracked cases, 2 groups matched by disease stage and tumor molecular subtypes were formed using 1:2 pseudo-randomization: the study group (n = 63, age ≤ 25 years) and the control group (n = 126, age 25 years). The distribution of clinical stages was identical in both groups: in the study group, stage IA was observed in 11 patients (17.5 %), IIA in 18 (28.6 %), IIB in 13 (20.6 %), IIIA in 6 (9.5 %), IIIB in 7 (11.1 %), and IIIC in 8 (12.7 %); in the control group the corresponding numbers were 22, 36, 26, 12, 14, and 16 cases, respectively (the same proportions). Overall survival and recurrence-free survival (RFS) were assessed. Results. The analysis revealed a statistically significant decrease in RFS in the group of young patients. The median RFS was 73.9 months compared to 82.8 months in the control group, which is consistent with the survival analysis results (p = 0.027). The 5-year RFS was significantly lower – 55.7 % versus 77.1 %, and the 10-year RFS was 36.3 % versus 49.8 % (p = 0.027). Regarding overall survival, although the median and 5-year survival rates in the ≤ 25 years group were also lower (149.7 months and 79 % versus 157.3 months and 89 %, respectively), the difference did not reach statistical significance (p = 0.229). Conclusion. Patients with breast cancer aged ≤ 25 years have significantly lower recurrence-free survival, confirming the concept of more aggressive disease course in young age, likely associated with adverse biological features of the tumors. These findings underscore the need to identify modifiable prognostic factors and develop more effective treatment strategies for this patient category.
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 69-75
Open AccessLong-term outcomes in young patients with breast cancer. Multicenter, matched-cohort study
Background. Despite existing clinical guidelines, representative data on breast cancer outcomes in patients aged 25 years and younger remain limited. Aim. To analyze long-term survival in this age group. Materials and methods. We conducted a retrospective, multicenter study that included patients treated between 2008 and 2020. From 552 tracked cases, 2 groups matched by disease stage and tumor molecular subtypes were formed using 1:2 pseudo-randomization: the study group (n = 63, age ≤ 25 years) and the control group (n = 126, age 25 years). The distribution of clinical stages was identical in both groups: in the study group, stage IA was observed in 11 patients (17.5 %), IIA in 18 (28.6 %), IIB in 13 (20.6 %), IIIA in 6 (9.5 %), IIIB in 7 (11.1 %), and IIIC in 8 (12.7 %); in the control group the corresponding numbers were 22, 36, 26, 12, 14, and 16 cases, respectively (the same proportions). Overall survival and recurrence-free survival (RFS) were assessed. Results. The analysis revealed a statistically significant decrease in RFS in the group of young patients. The median RFS was 73.9 months compared to 82.8 months in the control group, which is consistent with the survival analysis results (p = 0.027). The 5-year RFS was significantly lower – 55.7 % versus 77.1 %, and the 10-year RFS was 36.3 % versus 49.8 % (p = 0.027). Regarding overall survival, although the median and 5-year survival rates in the ≤ 25 years group were also lower (149.7 months and 79 % versus 157.3 months and 89 %, respectively), the difference did not reach statistical significance (p = 0.229). Conclusion. Patients with breast cancer aged ≤ 25 years have significantly lower recurrence-free survival, confirming the concept of more aggressive disease course in young age, likely associated with adverse biological features of the tumors. These findings underscore the need to identify modifiable prognostic factors and develop more effective treatment strategies for this patient category.
- Open Access
- 29 November 2024
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 14 (4) , 20-30
Limitations of CDX and PDX methods using for cultivation of malignant ovarian neoplasms and their mathematical justification
The article presents information on the most popular methods of culturing human malignant neoplasms to implement the obtained fundamental knowledge into the basis of translational research in oncology. A brief description of each of them allows you to decide on the possibility of including the technique in experimental work. The first approximation to the formation of the logic of the mathematical justification of the design of an experiment on modeling human malignant neoplasms is given.Also, using the example of a brief description of the original design of the experiment of scientists from the Khanty-Mansiysk State Medical Academy and the Tyumen State Medical University, the logic of constructing the design of such an experiment as part of the research work is demonstrated. An idea is formed about the need to include fundamental and translational stages in clinical experimental work as part of a unified strategy for responding to the great challenges of personalized medicine. An idea is formed about the need to include fundamental and translational stages in clinical experimental work as part of a unified strategy for responding to the great challenges of personalized medicine.
- 29 November 2024
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 14 (4) , 20-30
Open AccessLimitations of CDX and PDX methods using for cultivation of malignant ovarian neoplasms and their mathematical justification
The article presents information on the most popular methods of culturing human malignant neoplasms to implement the obtained fundamental knowledge into the basis of translational research in oncology. A brief description of each of them allows you to decide on the possibility of including the technique in experimental work. The first approximation to the formation of the logic of the mathematical justification of the design of an experiment on modeling human malignant neoplasms is given.Also, using the example of a brief description of the original design of the experiment of scientists from the Khanty-Mansiysk State Medical Academy and the Tyumen State Medical University, the logic of constructing the design of such an experiment as part of the research work is demonstrated. An idea is formed about the need to include fundamental and translational stages in clinical experimental work as part of a unified strategy for responding to the great challenges of personalized medicine. An idea is formed about the need to include fundamental and translational stages in clinical experimental work as part of a unified strategy for responding to the great challenges of personalized medicine.